James C. Clemmer - Jul 17, 2024 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Role
President and CEO, Director
Signature
/s/ Stephen A. Trowbridge, as Attorney in Fact
Stock symbol
ANGO
Transactions as of
Jul 17, 2024
Transactions value $
$0
Form type
4
Date filed
7/19/2024, 05:18 PM
Previous filing
Apr 8, 2024
Next filing
Jul 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANGO Common Stock Award $0 +106K +19.63% $0.00 645K Jul 17, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANGO Performance Right Award $0 +212K $0.00 212K Jul 17, 2024 Common Stock 212K Direct F2
transaction ANGO Non-Qualified Stock Option (right to buy) Award $0 +208K $0.00 208K Jul 19, 2023 Common Stock 208K $7.40 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The acquisition of 105,811 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 105,811 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 17, 2025, such that 25% of the restricted stock units will vest on each of July 17, 2025, 2026, 2027 and 2028.
F2 Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.
F3 These stock options vest in four equal annual installments beginning on July 17, 2025, such that 25% of the options will vest on each of July 17, 2025, 2026, 2027 and 2028.